70,000 Shares in Coya Therapeutics, Inc. (NASDAQ:COYA) Bought by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. acquired a new stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 70,000 shares of the company’s stock, valued at approximately $401,000. Newbridge Financial Services Group Inc. owned approximately 0.42% of Coya Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares in the last quarter. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the 3rd quarter worth $169,000. Finally, Renaissance Technologies LLC acquired a new position in Coya Therapeutics during the 2nd quarter valued at about $101,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Stock Down 2.4 %

Shares of NASDAQ:COYA opened at $6.83 on Monday. Coya Therapeutics, Inc. has a 52-week low of $4.75 and a 52-week high of $10.69. The stock has a market cap of $114.11 million, a price-to-earnings ratio of -10.51 and a beta of 0.47. The business has a 50-day moving average price of $5.87 and a 200-day moving average price of $6.39.

Wall Street Analysts Forecast Growth

COYA has been the subject of several recent analyst reports. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.